PARP inhibitor Zejula could be reimbursed as the primary maintenance therapy for ovarian cancer. However, it is pointed out that "regulatory agencies should change their perspectives" due to benefit standards. Kim Jaewon, professor of obstetrics and gynecology at Seoul National University Hospital, is taking Korea on the 7th. At the Zejula online meeting held by the restriction, he pointed out, "It is regrettable that only ovarian cancer patients with BRCA mutations have recognized primary maintenance benefits. This is in accordance with the stereotypes of regulators, and we need to change our perspective like in the United States."

Earlier, the Health Insurance Review and Assessment Service recognized